文献速递衰弱、肌少症与跌倒

孟德尔随机化识别肌少症潜在治疗靶点

Potential therapeutic targets for sarcopenia identified by Mendelian randomisation.
PubMed 文献 · Age Ageing · 2023-01-01

研究利用全基因组关联研究(GWAS)汇总数据与顺式蛋白位点遗传工具,在256,523名60岁及以上欧洲人中用顺式孟德尔随机化(MR)及多宇宙敏感性分析评估血浆蛋白与肌少症的因果关联。结果发现5种可成药血浆蛋白在全人群或女性人群中与肌少症存在因果关联,其中TNF12与HGF的作用与四肢瘦体重(ALM)相关,并已有临床试验药物。

要点

  • 全人群中HPT、AT1B2、ISLR2和TNF12与EWGSOP标准定义的肌少症风险存在因果关联。
  • 女性人群中AT1B2和TNFSF12与EWGSOP标准肌少症风险相关,HGF与NIH标准呈负相关。
  • TNF12与ALM呈负向因果关联,HGF与ALM呈正向因果关联,二者均有临床试验药物。

核心结论

  • 5种可成药血浆蛋白在全人群或女性人群中与肌少症存在因果关联,TNF12和HGF同时与ALM相关,提示潜在治疗靶点。

研究设计与样本

  • 采用顺式孟德尔随机化(MR)及多宇宙敏感性分析,肌少症汇总数据来自256,523名60岁及以上欧洲人的GWAS。
  • 纳入血浆蛋白质组分析研究的60种蛋白和其他研究的12种蛋白进行MR分析。

主要发现

  • 全人群中HPT、AT1B2、ISLR2和TNF12按EWGSOP标准与肌少症风险存在因果关联。
  • 女性人群中AT1B2和TNFSF12按EWGSOP标准与肌少症风险相关,HGF按NIH标准呈负向关联。
  • TNF12与ALM呈负向因果关联,HGF与ALM呈正向因果关联。

关键数值与推荐

  • 全人群4种蛋白(HPT、AT1B2、ISLR2、TNF12)与EWGSOP标准肌少症风险存在因果关联。
  • 女性人群AT1B2、TNFSF12与EWGSOP标准肌少症风险相关,HGF与NIH标准呈负向关联。
  • 所鉴定蛋白均为可成药靶点,TNF12和HGF的抑制剂已在其他疾病的临床试验中评估。

临床怎么用

  • 上述蛋白可作为肌少症潜在治疗靶点,但研究为遗传学因果推断,尚不能直接用于临床干预决策。

局限性

  • 研究基于欧洲血统60岁及以上人群的GWAS汇总数据,外推至其他人群需谨慎。
  • 结果来自孟德尔随机化分析,蛋白靶点的临床有效性与安全性仍需临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Identifying sarcopenia's causally associated plasma proteins would provide potential therapeutic targets. METHODS: We screened out sarcopenia-related proteins with genome-wide association studies (GWAS) summary data and cis-protein loci genetic instruments. Summary data of sarcopenia were obtained from a GWAS of 256,523 Europeans aged 60 years and over. The causal effects of the proteins were investigated by cis-Mendelian Randomisation (MR) and multiverse sensitivity analysis. We also explored the robust proteins' causal associations with appendicular lean mass (ALM) and surveyed their druggability and clinical development activities. RESULTS: In sum, 60 proteins from plasma proteome analysis studies and 12 from other studies were enrolled for MR analysis. In the whole population, four proteins (HPT, AT1B2, ISLR2 and TNF12) showed causal associations with the risk of sarcopenia according to the European Working Group on Sarcopenia in Older People (EWGSOP) criterion. In the female population, AT1B2 and TNFSF12 revealed causal associations with sarcopenia risk according to the EWGSOP criterion; HGF revealed a negative association according to the National Institutes of Health criterion. All of them were druggable, and the inhibitors of TNF12 and HGF were evaluated in clinical trials for other diseases. TNF12 also revealed a negative causal association with ALM, whereas HGF was positively causally associated with ALM. CONCLUSIONS: Five druggable plasma proteins revealed causal associations with sarcopenia in the whole or female populations. TNF12 and HGF were the targets of therapeutic agents evaluated in clinical trials, and they were also causally associated with ALM. Our study suggested the potential mechanisms and therapeutic targets for sarcopenia.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Jiang W, Zhan W, Zhou L, et al. Potential therapeutic targets for sarcopenia identified by Mendelian randomisation. Age Ageing. 2023. PMID: 36821647. doi:10.1093/ageing/afad024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。